Gain Therapeutics, Inc., a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas in Switzerland, Spain, the United States, and Australia. The company's drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease. Its lead drug candidate is GT-02287, which is currently in a Phase 1b study for the treatment of Parkinson's disease with or without a GBA1 mutation. The company has various small molecule drug candidates, which are in the discovery, research, and preclinical stages for the treatment of dementia with Lewy bodies, Alzheimer's disease, and Gaucher's disease, lysosomal storage disorders, metabolic disorders, and solid tumors. Gain Therapeutics, Inc. was founded in 2017 and is based in Bethesda, Maryland.…
Gain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
Gain Therapeutics (NASDAQ: GANX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Biotechnology industry, part of the Healthcare sector, and reports about 20 employees.
The shares were at 0.9994 USD on 20 November 2026, down 49.0% over 52 weeks. Its 52-week range is 0.9401 USD to 4.340 USD: the price is 77.0% below the high and 6.3% above the low.
Its market capitalisation is 44.50M USD.
Gain Therapeutics reports return on equity of -108.6% and an operating margin of 0.0%.
It holds more cash than debt, a net cash position of 11.02M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health.